Drug intelligence / Profile preview

D352

Development stage: Phase 1

Overview

D352 is a drug that was investigated in a clinical study (NCT06758661) to evaluate its drug-drug interaction and safety when co-administered with D794 in healthy adult volunteers. The study was conducted for dyslipidemia.

Targets

SLAMF6 (Signaling lymphocytic activation molecule family member 6)

Beyond the preview

Go deeper on D352.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D352.

Explore the full profile